Literature DB >> 8381225

The genomic structure of the human UFO receptor.

A S Schulz1, L Schleithoff, M Faust, C R Bartram, J W Janssen.   

Abstract

Using a DNA transfection-tumorigenicity assay we have recently identified the UFO oncogene. It encodes a tyrosine kinase receptor characterized by the juxtaposition of two immunoglobulin-like and two fibronectin type III repeats in its extracellular domain. Here we describe the genomic organization of the human UFO locus. The UFO receptor is encoded by 20 exons that are distributed over a region of 44 kb. Different isoforms of UFO mRNA are generated by alternative splicing of exon 10 and differential usage of two imperfect polyadenylation sites resulting in the presence or absence of 1.5-kb 3' untranslated sequences. Primer extension and S1 nuclease analyses revealed multiple transcriptional initiation sites including a major site 169 bp upstream of the translation start site. The promoter region is GC rich, lacks TATA and CAAT boxes, but contains potential recognition sites for a variety of trans-acting factors, including Sp1, AP-2 and the cyclic AMP response element-binding protein. Proto-UFO and its oncogenic counterpart exhibit identical cDNA and promoter regions sequences. Possible modes of UFO activation are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381225

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  Cataract- and lens-specific upregulation of ARK receptor tyrosine kinase in Emory mouse cataract.

Authors:  Nancy L Sheets; Bharesh K Chauhan; Eric Wawrousek; J Fielding Hejtmancik; Ales Cvekl; Marc Kantorow
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

Review 3.  Axl-dependent signalling: a clinical update.

Authors:  Vyacheslav A Korshunov
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

4.  Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway.

Authors:  K O'Donnell; I C Harkes; L Dougherty; I P Wicks
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 5.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 6.  Targeting TAM to Tame Pancreatic Cancer.

Authors:  Mitchell S von Itzstein; Michael C Burke; Rolf A Brekken; Todd A Aguilera; Herbert J Zeh; Muhammad Shaalan Beg
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

Review 7.  The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview.

Authors:  Martha Wium; Juliano D Paccez; Luiz F Zerbini
Journal:  Cells       Date:  2018-10-12       Impact factor: 6.600

Review 8.  AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.

Authors:  Italia Falcone; Fabiana Conciatori; Chiara Bazzichetto; Emilio Bria; Luisa Carbognin; Paola Malaguti; Gianluigi Ferretti; Francesco Cognetti; Michele Milella; Ludovica Ciuffreda
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

9.  Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.

Authors:  Omkara Lakshmi Veeranki; Zhimin Tong; Rashmi Dokey; Alicia Mejia; Jianhu Zhang; Yawei Qiao; Pankaj Kumar Singh; Riham Katkhuda; Barbara Mino; Ramesh Tailor; Jaime Rodriguez Canales; Roland Bassett; Jaffer Ajani; Ji Yuan Wu; Scott Kopetz; Mariela Blum; Wayne Hofstetter; Michael Tetzlaff; Sunil Krishnan; Steven H Lin; Dipen Maru
Journal:  Oncotarget       Date:  2019-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.